|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:approvedBy
|
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:ATCCode
|
gptkb:L04AA27
|
|
gptkbp:CASNumber
|
gptkb:162359-55-9
|
|
gptkbp:chemicalFormula
|
C19H33NO2
|
|
gptkbp:contraindication
|
gptkb:second-_or_third-degree_AV_block
stroke
pregnancy
recent myocardial infarction
severe untreated sleep apnea
|
|
gptkbp:drugClass
|
immunotherapy
|
|
gptkbp:drugInteraction
|
immunosuppressants
live vaccines
antiarrhythmic drugs
|
|
gptkbp:eliminationHalfLife
|
6-9 days
|
|
gptkbp:genericName
|
gptkb:fingolimod
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Gilenya
|
|
gptkbp:indication
|
relapsing forms of multiple sclerosis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:marketedAs
|
gptkb:Gilenya
gptkb:Fingolimod
|
|
gptkbp:mechanismOfAction
|
sphingosine-1-phosphate receptor modulator
|
|
gptkbp:monitors
|
eye examination
heart rate
blood pressure
liver function
|
|
gptkbp:patentExpired
|
2019 (US)
|
|
gptkbp:pregnancyCategory
|
gptkb:X_(US)
|
|
gptkbp:pregnancyWarning
|
may cause fetal harm
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:macular_edema
bradycardia
increased risk of infections
liver enzyme elevation
|
|
gptkbp:usedFor
|
multiple sclerosis
|
|
gptkbp:bfsParent
|
gptkb:Novartis
|
|
gptkbp:bfsLayer
|
4
|